Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > September 2017

« Previous month

ChromaTan to develop continuous purification tech with $2.5m US FDA grant

20-Sep-2017 - ChromaTan will develop an integrated and continuous downstream purification platform through provisions in the 21st Century Cures Act to support manufacturing initiatives.

EU distribution: BioCat on board the Vmax Express

20-Sep-2017 - SGI-DNA has selected BioCat to distribute its protein expression platform Vmax Express, which it says is more rapid than traditional expression systems.


US FDA stem cell enforcement challenged by state legislation

20-Sep-2017 - State legislation allowing unapproved stem cell treatments could undermine efforts by the US FDA to clampdown on unregistered clinics.

Fire ant venom to combat thick skin

19-Sep-2017 - Researchers say compounds from fire ant venom could be used to develop psoriasis treatments which limit skin-thickening side effects.

Brammer ups early phase manufacturing capacity

19-Sep-2017 - Brammer Bio has doubled its early phase manufacturing capacity at its Alachua, Florida-based site.

Catalent to buy Cook Pharmica for $950m in cash

19-Sep-2017 - Catalent Inc has announced it will buy Cook Pharmica for $950m (€792m) in cash to boost its high tech drug production business.

Bayer takes a shine to Berkeley Light's Beacon biologics workflow tech

19-Sep-2017 - Bayer has signed a deal to use Berkeley Lights’ automated biological workflow platform for cell line development and antibody discovery.

Samsung Bioepis will use CMOs to make Ontruzant if it is approved

19-Sep-2017 - Samsung Bioepis will use contractors to make its candidate Herceptin biosimilar Ontruzant if it goes on to be approved in Europe.

Synpromics expansion to support growing gene control business

19-Sep-2017 - Moving to a larger facility will help Scottish firm Synpromics Ltd increase its gene control and cell line services presence, the firm says.

Remicade biosimilar: J&J’s ‘fear and loathing’ subdued as Pfizer slugs it out

15-Sep-2017 - Fears of Remicade competition have not manifested in significant growth declines for Johnson & Johnson, but Pfizer says US payers and physicians are slowly getting comfortable with biosimilars.

US FDA approves Amgen and Allergan's Avastin biosimilar

15-Sep-2017 - US regulators have approved Amgen Inc’s Mvasi (bevacizumab-awwb), a biosimilar version of Roche’s monoclonal antibody (mAb) cancer treatment Avastin (bevacizumab). 

Kaneka Eurogentec to build biodrug production plant in Belgium

14-Sep-2017 - Kaneka Eurogentec has announced plans to build a biopharmaceutical manufacturing facility in Seraing, Belgium.

Momenta: WuXi single-use capacity expansion to support changing biosimilar demand

14-Sep-2017 - Momenta says flexibility built into its contract with WuXi Biologics will offset fluctuations in demand for global biosimilars.

Microtissue magic: 3D-printed tech for cell culture production 'degrades on demand'

14-Sep-2017 - Researchers at Brown University have developed a 3D printing technique which they say could be used to make cell cultures for biopharmaceutical production.


Alexion to close Rhode Island Soliris plant and cut jobs

13-Sep-2017 - Alexion will close its Rhode Island manufacturing facility as part of a cost cutting plan that will also see it reduce its workforce by 20% over the next year.

Fujifilm Diosynth Biotechnologies opens new UK lab

13-Sep-2017 - Fujifilm Diosynth Biotechnologies has opened a $9m process development laboratory in Teeside, UK.


Biocon says Malaysia insulin plant passed HPRA inspection

12-Sep-2017 - Biocon says its insulin plant in Malaysia has been awarded a European GMP certificate after an inspection by Ireland’s Health Products Regulatory Authority (HPRA).

Expression yourself: Win an iPad in our bioprocessing survey

12-Sep-2017 - Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.

Merck boosts cancer pipeline in €464m deal

08-Sep-2017 - Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.

CGT Catapult teams with TrakCel for cell and gene therapy tracking

08-Sep-2017 - Firms that make therapies at the Cell and Gene Therapy Catapult facility in Stevenage, UK will track their products using tech provided by TrakCel.

Lilly preserves biomanfacturing network amid $500m cost-saving restructure

08-Sep-2017 - Eli Lilly has announced a restructuring plan which will cut around 3,500 jobs but biomanufacturing will remain largely unaffected.

Celltrion confident in quality of biosimilar supply despite US FDA 483

07-Sep-2017 - Celltrion Inc has received a FDA Form 483 with 12 observations but remains confident no exported biosimilar products have any quality issues.


Spain OKs TiGenix's bigger cell therapy plant as firm preps for Cx601

06-Sep-2017 - Spain has licensed TiGenix NV's expanded Madrid plant paving the way for a potential European launch of Cx601, its cell therapy for the Crohn's disease complications.

GE launches cell therapy thawing tech

06-Sep-2017 - GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.

Roche to up Russian Gazyva supply through local fill/finish deal

06-Sep-2017 - Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa.

« Previous month

Key Industry Events


Access all events listing

Our events, Shows & Conferences...